Abstract
This commentary refers to the recent clinical study by Cohen et al., which investigated the efficacy of denosumab, a neutralizing antibody against receptor activator of nuclear-factor κB ligand (RANKL) in blocking structural joint damage in patients with rheumatoid arthritis. RANKL is an essential factor for the differentiation and activation of osteoclasts and for bone resorption. Therapeutic targeting of RANKL in patients with rheumatoid arthritis is, therefore, considered a promising tool for inhibiting the erosive joint damage that results from osteoclast-mediated bone resorption. A series of preclinical studies has suggested that RANKL has a key role in structural joint damage and can, therefore, be considered an interesting therapeutic target for blocking joint damage associated with arthritis. The study by Cohen et al. has highlighted these concepts by showing that blockade of RANKL with a neutralizing antibody halts structural deterioration of joints effectively in patients with rheumatoid arthritis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Tumor necrosis factor-alpha promotes survival in methotrexate-exposed macrophages by an NF-kappaB-dependent pathway
Arthritis Research & Therapy Open Access 15 February 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lacey DL et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165–176
McClung MR et al. (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821–831
Schett G et al. (2006) Mechanisms of Disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 1: 47–54
Cohen SB et al. (2008) Denosumab treatment effects on structural damage, bone mineral density and bone turover in rheumatoid arthritis. Arthritis Rheum 58: 1299–1309
Gravallese EM et al. (1998) Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 152: 943–951
McInnes IB and Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7: 429–442
Shigeyama Y et al. (2000) Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 43: 2523–2530
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Schett, G., David, JP. Denosumab—a novel strategy to prevent structural joint damage in patients with RA?. Nat Rev Rheumatol 4, 634–635 (2008). https://doi.org/10.1038/ncprheum0927
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0927
This article is cited by
-
Tumor necrosis factor-alpha promotes survival in methotrexate-exposed macrophages by an NF-kappaB-dependent pathway
Arthritis Research & Therapy (2011)